Cyteir Therapeutics Inc. (CYT)
NASDAQ: CYT
· Real-Time Price · USD
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 9:00 PM
Cyteir Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 129.24M | 133.63M | 137.2M | 147.12M | 153.89M | 166.4M | 177.38M | 189.72M | 199.82M | 198.64M | 84.19M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | 259K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 261K | 260K | n/a | 2.32M | 2.48M | 2.63M | 2.88M | 256K | 256K | 256K | 972K |
Receivables | n/a | 95K | 252K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | -17K | -95K | -252K | n/a | n/a | n/a | n/a | -38K | n/a | n/a | n/a |
Other Current Assets | 1.4M | 183K | 1.19M | 2.09M | 3.46M | 3.31M | 3.6M | 3.35M | 4.4M | 1.67M | 1.19M |
Total Current Assets | 130.64M | 133.91M | 138.39M | 149.21M | 157.35M | 169.71M | 180.99M | 193.08M | 204.22M | 200.31M | 85.39M |
Property-Plant & Equipment | 105K | 215K | 323K | 1.7M | 1.87M | 2.03M | 2.1M | 2.06M | 1.63M | 1.49M | 1.43M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 366K | 475K | 582K | 4.02M | 4.35M | 4.66M | 4.97M | 2.31M | 1.89M | 1.75M | 2.4M |
Total Assets | 131.01M | 134.39M | 138.98M | 153.23M | 161.7M | 174.37M | 185.96M | 195.39M | 206.11M | 202.05M | 87.79M |
Account Payables | 508K | 1.34M | 674K | 1.13M | 1.67M | 3.61M | 3.51M | 1.78M | 3.28M | 3.51M | 2.81M |
Deferred Revenue | -16K | -57K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 16K | 57K | 98K | 889K | 900K | 893K | 887K | n/a | n/a | n/a | n/a |
Other Current Liabilities | 5.45M | 5.18M | 3.19M | 3.3M | 3.25M | 4M | 4.76M | 5.73M | 4.25M | 3.93M | 1.46M |
Total Current Liabilities | 5.97M | 6.58M | 3.96M | 5.32M | 5.82M | 8.51M | 9.15M | 7.51M | 7.53M | 7.44M | 4.26M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 9K | 22K | 39K | 1.63M | 1.85M | 2.08M | 2.3M | 585K | 737K | 754K | 138.03M |
Total Long-Term Liabilities | 9K | 22K | 39K | 1.63M | 1.85M | 2.08M | 2.3M | 585K | 737K | 754K | 138.03M |
Total Liabilities | 5.98M | 6.6M | 4M | 6.95M | 7.66M | 10.58M | 11.46M | 8.1M | 8.27M | 8.2M | 142.29M |
Total Debt | 16K | 57K | 98K | 889K | 900K | 893K | 887K | n/a | n/a | n/a | n/a |
Common Stock | 35K | 35K | 35K | 35K | 35K | 35K | 35K | 35K | 35K | 34K | 2K |
Retained Earnings | -162.54M | -159M | -150.6M | -138.11M | -129.32M | -118.28M | -106.16M | -92.05M | -80.24M | -68.53M | -57.24M |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | n/a | -185.96M | n/a | -206.11M | -202.05M | n/a |
Shareholders Equity | 125.03M | 127.79M | 134.98M | 146.29M | 154.03M | 163.78M | 174.5M | 187.29M | 197.84M | 193.85M | -54.5M |
Total Investments | n/a | n/a | 259K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |